Azacitidine
Myeloid Malignancy
Molecular Partners AGSmall moleculePhase 2Active
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 89/ 100
Competitive context
29 Active assets in the Myeloid Malignancy cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Mitoxantrone First Affiliated Hospital of Zhejiang University | Phase 3 | BBB |
Cytosin-Arabinosid First Affiliated Hospital of Zhejiang University | Phase 3 | BBB |
Cladribine University of Washington | Phase 2 | BBB |
Cyclophosphamide Prelude Therapeutics | Phase 3 | BB |
Venetoclax First Affiliated Hospital of Zhejiang University | Phase 3 | BB |
View all 49 →
Same molecule, other indications
Azacitidine is also rated in:
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
73 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →